New triple therapy aims to shrink untreatable liver tumors
NCT ID NCT07521852
First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 2 times
Summary
This study tests a new drug (CVM-1118) combined with an immunotherapy (sintilimab) and a procedure that blocks the tumor's blood supply (TACE) in people with liver cancer that cannot be cured but hasn't spread. About 40 adults will receive all three treatments to see if the combination can shrink tumors and control the disease. The goal is to find a better way to manage this type of liver cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
MengChao Hepatobiliary Hospital of Fujian Medical University
RECRUITINGFuzhou, Fujian, China
-
Zhongshan Hospital, Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink liver tumors?
- Ancient herbal mix could boost liver health in advanced cancer
- Double immune attack: new drug combo takes on advanced liver cancer
- Breathing pure oxygen during an MRI may reveal whether liver cancer treatment is working
- Radiation and drug combo shows promise for tough liver cancers
- New immunotherapy combo aims to stop liver cancer return after surgery